PCM4EU - Personalised Cancer Medicine for all EU citizens
With 3.7 million new cases each year, cancer is one of the leading causes of death and morbidity in the EU. Personalised cancer medicine (PCM) has the potential to beat this disease. But currently, there is inequality in access to PCM between and within EU Member States.
As PCM is based on targeting driver mutations in tumours, its success depends on access to:
- next-generation sequencing-based molecular diagnostics,
- clinical decision support systems,
- trials to facilitate implementation of the PCM approach.
PCM4EU aims to improve the survival rates and quality of life of cancer patients in the EU using PCM based on best practices. The project consortium has a good track record in the implementation of molecular diagnostics in academically-led cross-border PCM trials in north-western Europe. This expertise will be made available to support a wider use and access to PCM in Europe.
- Project duration
- 1 Jan 2023 - 31 Dec 2024
- Project locations
- Overall budget
- €3 679 327
- EU contribution
- €2 943 45980% of the overall budget
- EU4health - Projects
- Diagnosis and treatment
- evaluate current standards and provide best practice guidelines and recommendations on implementation and interpretation of state-of-the-art genomic diagnostics, supporting their implementation and interpretation;
- support development of harmonised European mechanisms for interpretation of molecular and clinical data so that information from cohorts of patients with rare mutations/tumour types in several countries can be analysed simultaneously to obtain faster answers;
- ensure cross-border access to PCM;
- facilitate the incorporation of the project results into healthcare systems in a cost-effective way for future patients;
- provide education for all stakeholders, including physicians, pathologists, patients and decision makers.